<DOC>
	<DOCNO>NCT02220829</DOCNO>
	<brief_summary>Approximately 50 % -95 % prostate cancer patient undergo radiation therapy ( RT ) develop symptomatic urinary problem .These symptom significantly diminish patient 's quality life shortly therapy . Alpha1-blockers , Rapaflo , act decrease resistance urinary flow . This multi-institutional phase III trial design compare standard care versus preventive treatment Rapaflo prostate cancer patient , regardless risk group , whose treatment consist radical radiation therapy . We plan recruit 188 patient across Quebec randomize two arm : rapaflo prescribe start radiation therapy if/when symptom appear .</brief_summary>
	<brief_title>Comparative Study Use Alpha-Blockers Treat Symptoms Prostate Cancer Patients Undergoing Radiation Therapy</brief_title>
	<detailed_description>The efficacy Rapaflo treatment assess use International Prostate Symptom Score ( IPSS ) . The IPSS assess baseline RT , 4 week RT , last day RT , monthly thereafter total duration 6 month start RT . Patients 2 IPSS assessment 9 12 month . The total duration follow-up one year start RT . We compare rate IPSS increase Rapaflo group compare standard arm different time point ( 4 week , 6 week end treatment ) . We also determine rate IPSS return baseline 4 12 week end treatment . The rate therapy dependence 2 arm evaluate 20 26 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Silodosin</mesh_term>
	<mesh_term>Adrenergic alpha-Antagonists</mesh_term>
	<criteria>Adult male 18 year age old Patients confirm diagnosis adenocarcinoma prostate . The primary treatment external beam radiation therapy ( EBRT ) without high dose rate ( HDR ) brachytherapy boost . Clinical radiological diagnosis T1a T3b . No limitation respect Gleason score . No limitation respect total Prostatespecific Antigen ( PSA ) value . Karnofsky performance score ( KPS ) â‰¥ 70 . Small cell cancer prostate T4 disease , invade bladder rectum . Adjuvant salvage radiation therapy Brachy monotherapy KPS &lt; 70</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>alpha-blocker</keyword>
	<keyword>symptomatic urinary problem</keyword>
	<keyword>radiation therapy</keyword>
	<keyword>prostate cancer</keyword>
</DOC>